Ophthalmic Procurement Guide: Sterile Eye Drops and Diagnostic Dyes

Short answer: what you are actually buying in an ophthalmic supply line

Ophthalmology is one of the few pharmaceutical categories where the container is part of the medicine. A 0.4 mL single-dose unit, a multi-dose bottle, an amber ampoule of surgical dye and a sterile paper diagnostic strip are four different regulatory objects with four different failure modes — and are routinely bought, registered and dispensed by four different people inside the same hospital. Sourcing ophthalmics well therefore means fixing the presentation, the preservative strategy and the documentation package before comparing unit price.

Artemisine Medicines Technology runs this category from a dedicated sterile ophthalmic workshop with a stated output of 50 million eye-drop units per year, paired with a diagnostics business: ophthalmic dyes, fluorescein and lissamine green strips, Schirmer tear-test paper and rigid-contact-lens fitting strips. Medicines plus diagnostics from one supplier is what makes the line interesting to a distributor building a primary-eye-care programme. The complete eye care portfolio covers 20 products across five therapeutic pillars, inside a base of 208+ finished dosage products and medical devices sold to 50+ countries.

Why ophthalmic sourcing goes wrong

Four failure patterns account for most of the friction buyers report here. The preservative question gets decided by price when it should be decided by clinical protocol: chronic dry-eye and post-surgical regimens increasingly demand preservative-free (PF) single-dose units, while acute infectious courses still run on multi-dose bottles with a defined in-use discard period. Unit-dose and multi-dose are treated as interchangeable SKUs, when they differ in container-closure evidence, in-use shelf life and in what your authority will register under the label. Registration drifts when the final pack deviates from the dossiered one. And nobody in the chain owns light and temperature: surgical dyes are stored protected from light at 15–25 °C and must not be frozen, so a shipment left on a summer dock for two days can invalidate the product unnoticed.

The seven dimensions to specify

1. Preservative strategy and unit-dose technology

Ask first whether the product is preservative-free and single-dose, because it determines the whole downstream file. The catalogue already contains PF single-dose presentations — for example sodium hyaluronate eye drops 0.1% (1 mg/mL), supplied as a preservative-free 0.4 mL single-dose unit, packed 1 pic × 10 per box and stored at 15–30 °C protected from light. Where no catalogue presentation fits, Artemisine operates as an eye-drop CDMO with preservative-free single-dose unit technology, covering formulation development, sterility assurance, container-closure integrity testing and full CTD documentation.

2. Sterility assurance and the cleanroom evidence behind it

An ophthalmic dossier is only as strong as the aseptic story in it. Artemisine's workshops are built to China GMP requirements and follow the WHO GMP framework (WHO Technical Report Series), and the site passed China GMP on-site inspection again in 2026. Cleanrooms are classified Grade A to D per WHO GMP, with sterile filling in a Grade A zone over a Grade B background and at least 10 Pa positive-pressure differential between adjacent grades. Environmental monitoring runs on a WHO-defined schedule with alert and action limits.

3. Water, excipients and material control

Eye drops are aqueous products, so the water train is part of the product. Artemisine produces purified water through triple-stage reverse osmosis, purifies it further by multi-effect distillation to Water for Injection quality, circulates it above 70 °C to prevent microbial growth, and monitors conductivity and TOC continuously with offline microbial and endotoxin testing. Active ingredients and excipients are controlled to pharmacopoeial requirements (BP / USP / EP / CP monographs) through supplier qualification and audit, quarantine and dedicated sampling, full monograph testing, and automatic retest flagging.

4. The registration file you will actually receive

The document package is the product as far as your regulator is concerned. Every batch ships with a Certificate of Analysis, and for market registration Artemisine provides COPP, DMF and CTD-format dossiers, plus legalisation support where the destination authority requires it. GMP certificates, water system validation summaries, stability data and quality agreements are available for your submission, and on-site and remote audits are welcome. The quality system behind that package applies deviation investigation with tracked CAPA, validated change control, an Annual Product Quality Review per product and independent QA batch-record release. Lab methods include HPLC and GC.

5. Capacity, stability and shelf life you can put on the label

Ask for line output rather than a generic capacity claim. The sterile eye-drop line is stated at 50 million pieces per year — the site's capacity block lists 5 mL and 10 mL formats, while catalogue SKUs are 0.4 mL single-dose units with market-custom packing — within a base that also runs 300 million ampoule injections and 100 million IV infusion bottles annually. Stability data is generated under ICH Q1A and WHO guidelines, with long-term studies at 25 °C / 60 % RH and accelerated studies at 40 °C / 75 % RH. Retention samples of every batch are held one year beyond expiry, traceable from API lot to shipment.

6. Packaging that matches the market

Pack configuration is a commercial decision, not a packing detail. The ophthalmic range is packed to market requirement — bottle, blister or box — and individual SKUs carry defined packs: sodium hyaluronate 0.1% at 1 pic × 10 per box, sulfacetamide sodium 15% at 10 pics per box, and the Schirmer tear test strips at 2 pics per box. Standardise the pack before you standardise the price.

7. The diagnostics side of the basket

The diagnostics line is where most ophthalmic distributors under-buy. Artemisine supplies single-use sterile strips and contrast agents across three catalogue entries: tear-secretion filter paper (Schirmer test), rigid-contact-lens fitting strips and fluorescein sodium ophthalmic test strips for fundus angiography. The Schirmer strips are absorbent Whatman No. 41 paper, approximately 5 mm wide and 35 mm long, supplied sterile for single use with a printed 0–35 mm scale, sterilised by gamma irradiation or ethylene oxide and individually pouch-wrapped. The rigid-contact-lens fitting strips carry 1 mg fluorescein sodium USP per sterile strip, packed at 100 strips per box, and the fundus angiography product ships in a 5 mL amber ampoule, five per box. On the medicine side of the same line, the trypan blue ophthalmic solution 0.6% (3 mL) is a sterile surgical staining solution for intraocular use by qualified ophthalmic surgeons — not for self-administration — used to stain the anterior lens capsule during cataract surgery, stored protected from light and not frozen.

What Artemisine can supply in this line

The ophthalmic range covers the five pillars of primary eye care: antibiotics (moxifloxacin hydrochloride eye drops 0.5% (5 mg/mL) in 0.4 mL single-dose units, plus ofloxacin 0.3%, chloramphenicol 0.5%, gentamicin 0.3%, neomycin 40000 IU/mL, kanamycin 0.5% and lincomycin 2.5%); antivirals (acyclovir 1% and ribavirin 0.5%); anti-inflammatories (dexamethasone sodium phosphate 1%); allergy relief (sodium cromoglicate 2%); and lubricants (sodium hyaluronate 0.1%, hypromellose 0.5% and taurine 5%). Across these SKUs the stated release standard is BP / ENTERPRISE, and the document set is COA, COPP, DMF and CTD dossiers.

Two things distinguish this line commercially. The first is the CDMO option: a preservative-free unit-dose presentation, an alternative strength or a different label set is a development project rather than a stock item. The second is the OEM path — OEM packaging and private-label production with customised formulation, packaging and documentation, subject to the regulatory requirements of the destination market, so a distributor can launch under its own brand. The claims behind all of this are set out on the quality and GMP page and the company profile.

A procurement checklist you can run this quarter

1. Fix the presentation before the price. Single-dose unit, multi-dose bottle or amber ampoule — a fixed line in the enquiry, because it changes the file.
2. Ask for the container-closure integrity and aseptic evidence. Grade A over Grade B filling, CCI testing, environmental monitoring schedule, and the release certificate for each batch.
3. Request the full document package up front. COA, COPP, DMF, CTD dossier, GMP certificate, water system validation summary, stability data and quality agreements — so you can file without waiting on the first shipment.
4. Confirm storage and transit conditions in writing. For dyes and light-sensitive solutions, state the required range (15–25 °C, protected from light, do not freeze) and confirm the route that will hold it.
5. Test the supply chain with the diagnostics line. Diagnostic strips and ampoules are low-cost, high-frequency items that reveal lead-time and logistics performance faster than a bulk eye-drop order.
6. Get MOQ and lead time confirmed against a real requirement. MOQ depends on the product, regular items are held in stock for fast delivery, and the export team confirms stock, MOQ and dated lead time within 24 hours once you name the product, quantity and destination market.
7. Put your inquiry in writing on the first message. Artemisine replies within 24 hours; enquiries run through the contact page with the product name, quantity, destination market and required documents.

Start from the ophthalmic catalogue and the ophthalmic diagnostics category to assemble the basket, then request the quotation.

Frequently asked questions

Source: dosing and clinical reference summarised from the WHO Model Formulary and WHO Model List of Essential Medicines, World Health Organization; sterile-fill and diagnostic capability facts from Artemisine GMP documentation. This guide is for buyer education only — clinical decisions must follow the locally approved product insert and national treatment guidelines.